8 results about "Tnfα inhibitors" patented technology

The invention discloses a macrocyclic compound as well as a pharmaceutical composition and application thereof. The present invention provides a compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compounds of the present disclosure are useful as inhibitors of TNF [alpha] and are useful in the treatment of inflammation and autoimmune diseases.

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and / or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and / or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

This application provides a method for treating cancer in an individual, the method comprising administering a myeloid cell activator or myeloid cell activation therapy (such as a TLR agonist or STING agonist) and a TNFα inhibitor to the individual. In some cases, the method further comprises administering an SHP-1 inhibitor and / or a tyrosine kinase inhibitor to the individual, and optionally further comprising administering a lymphocyte activator, such as a cytokine (such as IL-2) and / or an immune checkpoint inhibitor (such as anti-PD-1).

The present application provides a method of treating a cancer in an individual that involves administering to the individual a lymphocyte activating agent (e.g., a T cell activating agent) and an agent that inhibits SHP-1 signaling (e.g., TPI-1, PTP-1). In some cases, the method optionally further involves administering a TNFα inhibitor and / or a pro-inflammatory agent (such as TLR or STING agonists).

Described herein are methods of treating an immunotherapy-associated adverse event in a subject in need thereof comprising detecting a level of NKG2D receptor ligand polypeptide (and optionally IL-18) in a sample form the subject; and (b) administering either (1) a corticosteroid or (2) a TNFα inhibitor or an integrin inhibitor to the subject.

Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.

The present disclosure provides methods of treating disease (e.g., digestive diseases) by administering an antibody or an antigen portion thereof that binds to sLeA and a TNFα inhibitor, as well as pharmaceutical compositions related thereto.

The present application provides a method of treating a cancer in an individual that involves administering to the individual a lymphocyte activating agent (e.g., a T cell activating agent) and an agent that inhibits SHP-1 signaling (e.g., TPI-1, PTP-1). In some cases, the method optionally further involves administering a TNFα inhibitor and / or a pro-inflammatory agent (such as TLR or STING agonists).